Abstract
Genomic expression profiling of tumors is used to individualize early-stage breast cancer treatment. However, very little is known about patients’ understanding of and desired information about these tests, such as Oncotype DX. We addressed these issues via a survey mailed to 130 early-stage breast cancer patients who received an Oncotype DX test result. The survey assessed understanding (14 items), information desired about genomic expression profiling tests, and if and where they sought information about Oncotype DX. Sixty-four surveys were returned. Overall, 54% of the knowledge items were answered correctly. Patients wanted education about genomic tests in many areas. Overall, 62% sought information about the test, primarily from the Internet (48%) and doctor or health care provider (31%). In sum, patients’ misunderstanding of genomic tests abound, necessitating better educational efforts on behalf of health care systems to meet their needs for varied information through different communication channels.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Harris L, Fritsche H, Mennel R et al (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25(33):5287–5312
National Comprehensive Cancer Network (2011). Practice guidelines in oncology for breast cancer (Version 2.2011). National Comprehensive Cancer Network, Inc.
Lo SS, Mumby PB, Norton J, Rychlik K, Smerage J, Kash J, Chew HK, Gaynor ER, et al. (2010) Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol 28(10):1671–1676.
American Cancer Society (2010) Breast cancer profiler tool. Accessed 17 February 2011
Goldstein LJ, Gray R, Badve S et al (2008) Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol 26(25):4063–4071
Richman AR, Tzeng JP, Carey LA, Retel VP, Brewer NT (2011) Knowledge of genomic testing among early-stage breast cancer patients. Psychooncology 20(1):28–35
Bernstam EV, Walji MF, Sagaram S, Sagaram D, Johnson CW, Meric-Bernstam F (2008) Commonly cited website quality criteria are not effective at identifying inaccurate online information about breast cancer. Cancer 112(6):1206–1213
Beaton C, Codd RJ, Holland PA, Gateley CA (2008) Evaluation of the quality and accuracy of information regarding aromatase inhibitors available on the Internet. The Breast Journal 14(4):366–368
Schwartz MD, Lerman C, Brogan B et al (2004) Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients. J Clin Oncol 22(10):1823–1829
Thompson AM, Johnson A, Quinlan P et al (2011) Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy. Breast Cancer Res Treat 125(1):279–287
Slodkowska EA, Ross JS (2009) MammaPrint 70-gene signature: another milestone in personalized medical care for breast cancer patients. Expert Rev Mol Diagn 9(5):417–422
Acknowledgments
Funding support was through the Miles for Moffitt Milestone Award and the Anthony Marchionne Foundation. We thank Dr. Noel Brewer for his helpful discussions and commentary on assessing breast cancer patients understanding of genomic tests.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lipkus, I.M., Vadaparampil, S.T., Jacobsen, P.B. et al. Knowledge About Genomic Recurrence Risk Testing Among Breast Cancer Survivors. J Canc Educ 26, 664–669 (2011). https://doi.org/10.1007/s13187-011-0248-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13187-011-0248-5